Outlook Therapeutics CEO buys stock and warrants

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.

Insider Trade Summary

Net Buyer: 303,030 shares

Net Buy 2 txns

Insider Jahr Robert Charles

Role Chief Executive Officer

Bought 303,030 shs

Type	Security	Shares	Price	Value
Purchase	Warrants (right to buy) F2, F1	151,515	--	--
Purchase	Common Stock F1	151,515	--	--

Holdings After Transaction: Warrants (right to buy) — 151,515 contracts (Direct); Common Stock — 151,515 shares (Direct)

Footnotes (2)

1. F1. On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
2. F2. The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.

Key Figures

Common shares purchased: 151,515 shares Warrants purchased: 151,515 warrants Combined offering price: $0.99 +3 more

6 metrics

Common shares purchased 151,515 shares Common stock acquired by CEO on August 14, 2026

Warrants purchased 151,515 warrants Warrants acquired with common stock in underwritten public offering

Combined offering price $0.99 Per share of common stock and accompanying warrant in the offering

Warrant exercise price $1.10 Exercise price per share for the acquired warrants

Warrant expiration date August 14, 2031 Five years from the date of issuance

Total net shares bought 303,030 securities Sum of common shares and underlying warrant shares reported as net buy

Key Terms

underwritten public offering, accompanying warrants, combined public offering price, exercisable immediately

4 terms

underwritten public offering financial

"acquired 151,515 shares of common stock and accompanying warrants ... in the Issuer's underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

accompanying warrants financial

"shares of common stock and accompanying warrants to purchase 151,515 shares of common stock"

Securities called accompanying warrants are options issued together with another financing instrument—often bonds or preferred shares—that give the holder the right to buy common stock at a set price for a limited time. Think of them like detachable coupons included with a loan that can be redeemed later for stock; they matter to investors because they can dilute existing ownership if exercised and add potential upside tied to the issuer’s future share price.

combined public offering price financial

"for a combined public offering price of $0.99 per share of common stock and accompanying warrant"

exercisable immediately financial

"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Outlook Therapeutics (OTLK) CEO Robert Charles Jahr buy on August 14, 2026?

Robert Charles Jahr bought 151,515 shares of common stock and 151,515 accompanying warrants of Outlook Therapeutics on August 14, 2026 in an underwritten public offering, as disclosed in the Form 4 filing.

At what price did the OTLK CEO purchase the common stock and warrants?

The CEO purchased the securities at a combined public offering price of $0.99 per share of common stock and accompanying warrant in the underwritten public offering, according to the Form 4 footnote.

What are the key terms of the warrants acquired by the OTLK CEO?

The acquired warrants are exercisable immediately at an exercise price of $1.10 per share and expire five years after issuance, on August 14, 2031, and relate to 151,515 underlying shares of common stock.

How many Outlook Therapeutics (OTLK) shares does the CEO hold after these transactions?

After the reported transactions, Robert Charles Jahr directly holds 151,515 shares of common stock and 151,515 warrants, as shown in the post-transaction holdings reported for each line item.

Were the OTLK CEO’s August 14, 2026 purchases under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and no footnote describes a trading plan, so the reported August 14, 2026 purchases are not identified as being made under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 08:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jahr Robert Charles

(Last) (First) (Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		P		151,515	A	(1)	151,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (right to buy)(2)	$1.1	08/14/2026		P		151,515		08/14/2026	08/14/2031	Common Stock	151,515	(1)	151,515	D

Explanation of Responses:

1. On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.

2. The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.

	/s/ Lawrence Kenyon, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)